What is Cyteir Therapeutics Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Cyteir Therapeutics's Probability of Financial Distress (%) is 0.01%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Cyteir Therapeutics's Probability of Financial Distress (%)
For the Biotechnology subindustry, Cyteir Therapeutics's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyteir Therapeutics's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Cyteir Therapeutics's Probability of Financial Distress (%) falls into.
Cyteir Therapeutics Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | -9.61 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 0.01% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Cyteir Therapeutics (Cyteir Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Executives
| Novo Holdings A/s |
10 percent owner |
TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
| Joseph S Zakrzewski |
director |
509 WATERVIEW PLACE, NEW HOPE PA 18938 |
| John F Thero |
director |
C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921 |
| Adam M Veness |
officer: General Counsel |
C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036 |
| Stephen H. Sands |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
| Jeffrey Humphrey |
director |
C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142 |
| Droia Invest Ii Scsp |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Janwillem Naesens |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
| Sa Ihl |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Karen Hong |
director |
69 PARKSIDE DRIVE, PRINCETON NJ 08540 |
| Bv Wepaven |
10 percent owner |
BRUSSELSESTEENWEG 11, MEISE C9 1860 |
| Luc Verelst |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Df Ii Gp Sarl |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Timothy Romberger |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
| Racquel Bracken |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Cyteir Therapeutics (Cyteir Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYTT has been successfully added to your